Let me cross over," the men of Gilead would say to him, ``Are you an Ephraimite?" If he said, ``No," 6 then they would say to him, ``Say now, `Shibboleth.'" But he said, ``Sibboleth," for he could not ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

Gilead’s Q3 sales increased 7% year-over-year, including 13% year-over-year growth for Biktarvy. The Liver Disease portfolio sales increased 4% to $733 million, and Veklury sales increased 9% ...

With Gilead Sciences sprinting to a likely approval next year for its long-acting pre-exposure prophylaxis (PrEP) drug for HIV, the California company has a chance to one-up GSK. While the British ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

Gilead Sciences (GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from its COVID revenues and spurring investor anticipation for new products ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it ...

(Reuters) -Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its outlook for ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.